ICF: Microfluidic investigation of the role of transcapillary resistance and vascular permeability/normalisation on cancer outcomes via vasodilation

ICF：微流体研究跨毛细血管阻力和血管通透性/正常化通过血管舒张对癌症结果的影响

• 批准号: MR/Y000609/1
• 负责人: Sam Au
• 金额: $ 83.98万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FY000609%2F1
• 关键词: ICF; Microfluidic; investigation; role; transcapillary

In a landmark study involving 12,456 male patients diagnosed with colorectal cancer, those who took Sildenafil (marketed as Viagra) after diagnosis had over twice the odds of survivng for 10 years than those who did not. Sildenafil is commonly prescribed for erectile dysfunction and pulmonary arterial hypertension and acts by widening blood vessels (vasodilation). We propose that this drug influences colorectal cancer outcomes via two mechanisms: a) increasing the diameter of small vessels which inhibits tumour cell occlusion, a key step in metastasis progression and b) modification of the permeability and architecture of blood vessels, which may assist drug and immune cell delivery to tumours (Fig. 1). We will explore these hypothesis via 3 key aims: 1) development of a microvascular microfluidic platform that incorporates vasodilation induced by precapillary sphincter contraction, 2) investigate how vasodilation-mediated hemodynamic resistance influences tumour cell entrapment, invasion and metastasis formation, 3) explore the influence of endothelial permeability and microvascular normalisation on the tumour penetration and distribution of antibody therapeutics and immune cell infiltration & activity in microfluidic & mice models. Vasodilator drugs have long track records of safe use in humans and an understanding of how this drug influences cancer outcomes via the vasculature may provide a pathway to develop next generation vasodilator adjuvants without unwanted side effects for patients with cancer.

在一项涉及12456名被诊断为结直肠癌的男性患者的里程碑式研究中，那些在确诊后服用西地那非(市场名称为伟哥)的人比那些没有服用的人存活10年的几率高出一倍以上。西地那非通常用于治疗勃起功能障碍和肺动脉高压，通过扩张血管起作用。我们认为，这种药物通过两种机制影响结直肠癌的预后：a)增加小血管的直径，以抑制肿瘤细胞的闭塞，这是转移过程中的关键步骤；b)改变血管的通透性和结构，这可能有助于药物和免疫细胞向肿瘤的输送(图1)。我们将通过3个关键目标来探索这些假说：1)开发一个结合了毛细血管前括约肌收缩诱导的血管扩张的微血管微流体平台；2)研究血管扩张介导的血流动力学阻力如何影响肿瘤细胞的包裹、侵袭和转移的形成；3)在微流体和小鼠模型中，探索内皮通透性和微血管正常化对肿瘤穿透和分布以及免疫细胞渗透和活性的影响。血管扩张剂药物在人类安全使用方面有着长期的记录，了解这种药物如何通过血管系统影响癌症结果可能为癌症患者提供一条开发下一代血管扩张剂佐剂的途径，而不会产生不想要的副作用。